← Back to Screener
Immunovant, Inc. Common Stock (IMVT)
Price$28.53
Favorite Metrics
Price vs S&P 500 (26W)63.30%
Price vs S&P 500 (4W)18.01%
Market Capitalization$5.96B
All Metrics
Book Value / Share (Quarterly)$4.85
P/TBV (Annual)13.04x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.08
Price vs S&P 500 (YTD)11.13%
EPS (TTM)$-2.68
10-Day Avg Trading Volume1.72M
EPS Excl Extra (TTM)$-2.68
EPS (Annual)$-2.73
ROI (Annual)-58.50%
Cash / Share (Quarterly)$4.89
ROA (Last FY)-53.31%
EBITD / Share (TTM)$-2.80
ROE (5Y Avg)-43.90%
Cash Flow / Share (Annual)$-2.21
P/B Ratio6.05x
P/B Ratio (Quarterly)5.19x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-104.22x
ROA (TTM)-60.42%
EPS Incl Extra (Annual)$-2.73
Current Ratio (Annual)11.16x
Quick Ratio (Quarterly)15.03x
3-Month Avg Trading Volume1.56M
52-Week Price Return97.44%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.92
52-Week High$29.48
EPS Excl Extra (Annual)$-2.73
CapEx CAGR (5Y)90.82%
26-Week Price Return72.05%
Quick Ratio (Annual)10.42x
13-Week Price Return7.13%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)15.74x
Enterprise Value$4,968.968
Book Value / Share Growth (5Y)20.08%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.20
3-Month Return Std Dev50.09%
Net Income / Employee (TTM)$-1
ROE (Last FY)-58.50%
EPS Basic Excl Extra (Annual)$-2.73
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.68
Receivables Turnover (Annual)0.00x
ROI (TTM)-65.80%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.78
Price vs S&P 500 (52W)62.34%
Year-to-Date Return15.26%
5-Day Price Return16.64%
EPS Normalized (Annual)$-2.73
ROA (5Y Avg)-40.13%
Month-to-Date Return17.95%
Cash Flow / Share (TTM)$-1.96
EBITD / Share (Annual)$-2.89
ROI (5Y Avg)-43.90%
EPS Basic Excl Extra (TTM)$-2.68
P/TBV (Quarterly)18.77x
P/B Ratio (Annual)4.11x
Book Value / Share (Annual)$4.16
Price vs S&P 500 (13W)4.26%
Beta0.78x
Revenue / Share (TTM)$0.00
ROE (TTM)-65.80%
52-Week Low$13.36
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.09
4.17
4.17
4.13
Industry Peers — Biological Products(89)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IMVTImmunovant, Inc. Common Stock | — | — | — | — | $28.53 |
AMGNAmgen Inc | 5.20x | 9.95% | 73.30% | 2.93% | $350.16 |
GILDGilead Sciences Inc | 5.71x | 2.40% | 78.83% | 133.64% | $135.87 |
ARGXargenx SE American Depositary Shares | 12.59x | 89.56% | 150.91% | — | $834.45 |
BNTXBioNTech SE American Depositary Share | 9.06x | -11.81% | 84.21% | — | $105.19 |
BIIBBiogen Inc. Common Stock | 2.72x | 2.22% | 75.69% | -18.77% | $183.34 |
MRNAModerna, Inc. Common Stock | 10.91x | -39.93% | 70.32% | — | $54.59 |
NBIXNeurocrine Biosciences Inc | 4.64x | 21.45% | 98.18% | 2.31% | $131.59 |
EXELExelixis Inc | 4.89x | 6.85% | 96.39% | 31.10% | $43.61 |
TECHBio-Techne Corp. | 7.72x | 1.64% | 66.60% | -20.58% | $60.58 |
IBRXImmunityBio, Inc. Common Stock | 74.42x | 668.31% | 99.34% | — | $8.20 |
About
Immunovant is a clinical-stage immunology company developing treatments for autoimmune diseases driven by pathogenic IgG antibodies. Its lead candidate, IMVT-1402, is an FcRn inhibitor designed to reduce circulating IgG levels by blocking the receptor responsible for antibody recycling. The company focuses on research, development, and manufacturing of its therapeutic pipeline targeting autoimmune indications.